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ABSTRACT 
There is conflicting evidence surrounding the extent of changes in resting energy 
expenditure in cancer. This meta-analysis aimed establish the mean difference in 
resting energy expenditure, as kilojoules per kilogram fat-free mass, among cancer 
patients when compared to healthy control participants. The secondary aim was to 
determine differences among different cancer types. 
PubMed, Cochrane Library, Medline, Science Direct, Scopus, Web of Science, Wiley 
Online Library, and ProQuest Central were searched from the earliest records until 
March 2014. Studies were included if measured resting energy expenditure was 
reported as kilojoules or kilocalories per kilogram fat-free mass in adult subjects with 
cancer. Twenty seven studies were included in the meta-analysis. Fourteen studies 
included both cancer (n=1453) and control (n=1145) groups. The meta-analysis 
shows an average increase in resting energy expenditure of 9.66 (95% CI 3.34, 
15.98) kJ/kgFFM/day in cancer patients when compared to control participants. 
Heterogeneity was detected (p<0.001) which suggest variations in resting energy 
expenditure among cancer types. Elevations are most noticeable in patients with 
cancers of metabolically demanding organs. 
 
Comparison of resting energy expenditure between cancer subjects and 
healthy controls: A meta-analysis 
INTRODUCTION 
Changes in resting energy expenditure (REE) in cancer patients have been a 
controversial topic in literature. Substantial evidence supports elevations in REE 
during the tumour-bearing state. Elevated REE can potentially promote weight loss 
which can produce suboptimal clinical outcomes and increase morbidity and 
mortality risk[1]. Furthermore, elevated REE in conjunction with poor oral intake 
typically seen in cancer patients serve a significant role in accelerating weight loss 
and progressing to the development of malnutrition and cancer cachexia[2]. 
Current published findings depict inconsistencies in metabolic changes. Various 
authors propose that different cancers cause varying degrees of metabolic 
derangements. Fredrix et al[3] observed greater elevation of REE in lung cancer 
patients than gastric-colorectal cancer patients. Cao et al[4] found elevated REE in 
patients with oesophageal, gastric, pancreatic and lung cancers when compared to a 
healthy control group, whereas colorectal cancer patients showed no elevation in 
REE. Merli et al[5] and Xu et al[6] saw increased REE in patients with hepatocellular 
carcinoma and urologic cancer, respectively. However, authors for example Fearon 
et al[7] observed no significant differences in REE in colon and lung cancer patients 
and Trutschnigg et al[8] reported insignificant differences in advanced cancer 
patients.  
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Energy expenditure is the result of metabolic activities from various body tissues and 
organs. Major organs, such as the lungs and liver, are metabolically demanding and 
contribute to REE due to its continuous functioning and higher energy demands to 
perform metabolic processes irrespective of the body’s physical state and resting 
conditions. Fat free mass (FFM) is considered to be the largest contributor to REE 
suggested to provide 53-88% of REE variation[9, 10]. It would be valid to conclude 
that REE is decreased if loss of FFM becomes apparent under any circumstances, 
including cancer. This has not been the case as weight loss is frequently reported 
and observed in cancer patients. Weight loss associated with cancer is considered 
undesirable due to losses from either fat mass, FFM or both which serve important 
sources of energy during periods of acute hypermetabolism[1]. It has also been 
hypothesised that muscular atrophy typically observed in clinical settings is 
associated with poor tolerance of cancer treatment procedures and, hence, poor 
clinical outcomes[2].  
Tumour-bearing is proposed to elevate energy expenditure. However, there is 
uncertainty surrounding this. It has been suggested[2] that the tumour itself is 
unlikely to be the direct cause of elevated energy expenditure as tumours rarely 
contribute more than 5% of body weight. A plausible explanation may be that 
presence of tumours can exert an indirect effect on energy expenditure. The 
production of biochemical mediators stimulated by tumour growth may alter 
metabolism[2]and promote the inflammatory response which could contribute to 
hypermetabolism[11]. 
Although nutritional adequacy may be achieved to limit weight loss from FFM, the 
uncertainty of the metabolic environment may impede the maintenance or restoration 
of FFM[2, 12]. Identifying the extent to which REE is altered and understanding the 
cancer subtypes which cause the greatest increases in REE is important from a 
clinical perspective to limit anticipated weight loss as FFM and optimise clinical 
outcomes. The primary aim of this study was to establish the difference in REE 
between cancer patients and healthy controls. The secondary aim was to distinguish 
the differences in REE between cancer subgroups. As FFM is considered to be a 
large contributor to REE[9], it is appropriate to use measured REE per kg FFM. The 
use of healthy control groups was deemed appropriate to use as the standard for 
comparison to determine metabolic changes in cancer patients.  
METHODS 
Literature search 
Literature searches were conducted by VN using the databases PubMed, Cochrane 
Library, Medline, Science Direct, Scopus, Web of Science, Wiley Online Library, and 
ProQuest Central from the earliest record to March 2014 to obtain as many 
potentially relevant studies as possible. The following search terms, ‘resting energy 
expenditure’, ‘resting metabolic rate’, ‘basal metabolic rate’, ‘cancer’, and ‘neoplasm’ 
were used. Reference lists from included studies were reviewed to obtain additional 
relevant articles. The journals, Nutrition and Cancer, and Cancer and Metabolism 
were also searched using the above search terms. 
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Study selection 
Studies in which the title included one or more of the search terms were obtained 
from the literature search. The abstracts of the studies were reviewed by VN and MB 
for relevance. Studies were included if REE was expressed as kilojoules (kJ) or 
kilocalories (kcal) per kilogram FFM (REE/FFM), body composition was measured, 
participants were adult humans with cancer, healthy control groups were defined and 
used, statistical values presented as mean ± standard deviation (mean±SD) or mean 
± standard error of the mean (mean±SEM), and studies were published in English. 
Studies that measured REE, as REE/FFM, in cancer patients but did not include 
control groups were also included. Baseline REE measurements from intervention 
(pre-test/post-test) studies were included in the data set.  
Data extraction 
Study characteristics including the authors, source, publication year, cancer type, 
and the use of control subjects were tabulated. Baseline REE, presented as kJ or 
kcal per kg FFM, the number and type of subjects were collated into a Microsoft 
Office Excel spreadsheet. The method used to assess REE and the method used to 
assess body composition were also recorded, these were divided into more accurate 
and reliable methods (Dual energy x-ray absorptiometry DEXA, total body water, or 
total body potassium) and field methods (bioelectrical impedance assessment or 
skinfold anthropometry) to assess study quality. The baseline REE was the 
measurement prior to the cancer patients’ undergoing various treatments. 
Statistical analysis 
The baseline REE values and the number of participants (cancer patients and 
healthy controls) were used to complete the meta-analysis conducted by MB. The 
meta-analysis was conducted using STATA/IC V14 ( StataCorp LP, College Station, 
Tx) using the metan command[13].  All meta-analyses were conducted using 
random effects as heterogeneity was anticipated. Differences in REE amongst 
cancer types were also determined through a subgroup analysis.  In order to account 
for the use of the same control subjects for some studies the sample sizes were 
divided by the number of times the control group was used[14]. Additionally 
independent subgroups within a study were considered separately in the primary 
analysis[15]. In order to investigate potential confounding variables secondary 
analyses were also conducted to investigate the effect of healthy versus 
hospitalised/disease controls, weight losing versus weight stable cancer patients and 
controls, gender, and year of publication (pre or after 2000). Results are presented 
as weighted mean differences (WMD) between groups with 95% confidence intervals 
(95%CI). Statistical significance of the differences between the groups is calculated 
using metaregression (metareg in STATA V14.0). Study quality comparing those 
studies using a more accurate and reliable  measure of body composition 
assessment compared with a field measure  was also assessed using metagression. 
RESULTS 
Search results 
Figure 1 shows a flowchart of the extraction process. A total of 205 abstracts were 
obtained from the initial literature search, 178 abstracts were excluded on the 
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following basis: 85 studies expressed REE as kJ or kcal per day body weight or body 
cell mass, did not measure REE or body composition, or did not present data as 
mean±SD or mean±SEM; 56 were either review articles, educational papers, poster 
presentations, case reports, editorials or supplementary material; 12 studies were 
published in a language other than English; 11 studies were not on the subject of 
cancer; 7 studies were on animals; and 7 studies involved children. Twenty-seven 
studies were considered relevant for inclusion in this review[3-8, 11, 16-35] (Table 
1). Of these 27 studies, 14 studies included a healthy control group and the data 
from these studies were used to generate the meta-analysis (Figure 2). Two studies 
used the cancer patients as their own control. 
INSERT FIGURE 1  
INSERT TABLE 1 
INSERT FIGURE 2 
The forest plot shown in Figure 2 represents data obtained from 1453 cancer 
patients and 1145 control participants. The mean difference in REE/FFM between 
cancer patients and healthy controls is 9.66kJ/kgFFM/day (95% CI 3.34,15.98) which 
suggests an overall increase in REE in cancer patients. The test for heterogeneity 
(Chi2 =474.01 p < 0.001) suggested significant variation in REE/FFM among cancer 
types, the funnel plot presented in Figure 3 shows no evidence of publication bias 
but clearly emphasises the outlying value of the Wu et al study[35]. 
INSERT FIGURE 3 
The subgroup analysis (Figure 4) represents data from 12 of the 14 studies included 
in the meta-analysis. Two studies were not included in the analysis as they did not 
distinguish between cancer subtypes. The subgroup analysis derived mean 
differences in REE for 6 cancer types. Lung, head and neck/oesophageal, pancreatic  
and urological cancers had elevations of 6.52kJ/kg FFM/day, 21.06kJ/kg FFM/day, 
9.51kJ/kg FFM/day and 3.86kJ/kg FFM/day, respectively. Liver cancer illustrated the 
greatest elevation of 22.68kJ/kg FFM/day. All groups were significantly elevated with 
the exception of the gastric/colon cancer subgroup which showed an increase of 
1.99kJ/kg/day FFM (95% CI -0.58,4.53). The head, neck and oesophageal group 
elevation while high was not significant when the Wu study was included however 
the funnel plot demonstrates that this study is a clear outlier (consistent with the 
funnel plot in Figure 5), reanalysis without this study showed an elevation in the 
head, neck and oesophageal group of 6.04 kJ/kg/day FFM (95%CI  2.27, 9.81) 
indicating that REE is increased in this group. There was no evidence of publication 
bias (asymmetry) in the subgroup analysis (Figure 5).  
INSERT FIGURE 4 
INSERT FIGURE 5 
When controls were divided into healthy (WMD 14.74 95%CI 1.99,27.50 
kJ/kgFFM/day) or hospitalised/diseased (WMD 4.51 95%CI 1.00,8.01) elevation in 
REE in cancer patients were still significantly elevated in both groups and there was 
no difference between groups P=0.264. While there was no statistically significant 
difference between those identifying weight stable cancer patients and controls 
(WMD 6.55 95%CI 4.21, 8.90 kJ/kg FFM/day) and those identifying weight losing 
Nguyen 
 
6 
cancer patients and controls (WMD 4.49  95%CI -0.61,9.58 kJ/kg FFM/day) 
P=0.628, the elevation in the weight losing group only approached significance 
P=0.084. There was no effect of year of publication when a subgroup analysis was 
conducted dividing the dataset into publication year prior to (WMD 5.45 95%CI 1.54, 
9.35 kJ/kg FFM/day) or after 2000 (WMD 23.51 95%CI 7.70, 39.32 kJ/kg FFM/day) 
P=0.092, the wide CI for the post 2000 publications was influenced by the Wu et al 
paper (without this paper the WMD for the post 2000 papers was 4.60 95%CI 3.21, 
5.98 kJ/kg FFM day). Only 2 studies reported values by gender[29, 32], there was no 
significant effect using meta regression (males WMD -3.33 95%CI -10.14, 3.47 kJ/kg 
FFM/day and females WMD 3.75 95% CI -2.79, 10.29 kJ/kg FFM/day) P=0.179. All 
studies assessed resting energy expenditure using indirect calorimetry. The study 
quality assessment also showed no significant effect of body composition method 
more accurate and reliable method (WMD 4.02 95%CI 0.76, 7.28 kJ/kg FFM/day) 
compared with field method (WMD 12.14 95%CI 3.16, 21.11 kJ/kg FFM/day) 
P=0.494. 
DISCUSSION 
This study sought to determine the difference in REE between cancer patients and 
control subjects through summarizing data available from case-control and pre-
test/post-test studies. The meta-analysis derived from 16 studies suggested an 8-9% 
increase in REE in cancer patients when compared to healthy control groups.  
Cancer subtypes were shown in this analysis to generate different degrees of 
change in REE which is consistent with the previous notion of cancer type and 
tumour site affecting energy expenditure differently. While all subgroups showed an 
overall increase the difference was not significant for gastric and colon cancers and 
varied from 3.86 (95% CI 1.64, 6.08) kJ/kg FFM/day for Urologic cancers to 
22.68(95% CI 10.80, 34.56) kJ/kg FFM/day for the single study in liver cancer. 
Generally the FFM and to a lesser extent the fat mass (FM) are considered the major 
contributors to the REE. The metabolic activity of the organs however cannot be 
overlooked for their role in explaining variation in REE particularly if their function is 
altered by malignancy. Metabolic activity can be defined as the respective processes 
which occur at a cellular level to enable proper function of an organ. While a high 
metabolic rate in an organ does not necessarily mean a higher metabolic rate is 
generated from cancer in that tissue, in some cases metabolic activity has  been 
shown to be elevated in the diseased state with some major organs reportedly being 
more metabolically demanding than others. The lungs are considered as highly 
metabolically active organs and can utilise various substrates for normal function[36] 
which may somewhat explain for the elevations. According to the subgroup analysis 
(Figure 4) pancreatic cancer was also observed to generate an increase in REE. As 
the pancreas possesses both endocrine and exocrine functions, it has the potential 
to influence metabolism through inflammatory processes or the altered use of 
substrates. It has been suggested the flux of glucose in cancer patients may be 
elevated suggesting increased glucose demand[37]. Given that incomplete oxidation 
of glucose is to be replaced by fat oxidation[4] this could result in an increase in 
energy expenditure of 1050-1260kJ/day[37] which would correspond to 
approximately 0.9kg fat loss/month. This could be a possible explanation for the 
progressive weight loss often observed in cancer patients. According to the 
subgroup analysis (Figure 4), REE was also significantly altered in patients with 
head and neck and oesophageal cancer. Of the 3 studies reviewed, only 1 study was 
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included in the analyses. Langius et al[27] reported no significant differences 
between cancer patients and control participants.  
Findings from Silver et al[30] were similar to those reported by Langius et al[27] 
despite each of the patients in the study population being classified as either Stage 3 
or 4a for cancer progression[30]. Garcia-Peris et al[20]2 reported slightly higher 
metabolic rates to those of Langius et al[27] and Silver et al[30]. Interestingly, 
Garcia-Peris et al[20] observed a declining trend in REE amongst cancer patients 
during chemoradiotherapy which returned to pre-treatment values post treatment 
with FFM largely maintained. This strongly suggests REE is unlikely to be 
considerably altered in head and neck cancer patients and the post-treatment 
increase in REE was largely due to unchanged FFM[20].  
Four studies investigating REE in oesophageal cancer patients were included in this 
review and analyses. Thomson et al[32] reported unchanged REE among patients 
with oesophageal cancer whereas the results from three other studies reported 
elevations[4, 34, 35]. The mean REE reported by Wu et al[35] was much higher than 
those reported by other authors regarding oesophageal cancer (240.66kJ/kg/day 
FFM) and other cancer types. The extent of this elevation is questionable 
considering the reported mean REE from WL and WS patients were not elevated to 
such a degree. However, Wu et al[35] have reported inflammatory responses 
amongst cancer patients. Similarly, a number of authors[8, 11, 31]studying other 
cancer types have associated elevated REE with inflammatory cytokines, such as C-
reactive protein (CRP), interleukins 1 and 6 (IL-1; IL-6) and tumour necrosis factor 
(TNF). It has been suggested the contribution of humoral factors to hypermetabolism 
and cancer cachexia may be mediated by these cytokines and promote increased 
proteolysis, lipolysis and various glucose-synthesising pathways[38, 39].  This theory 
could be valid and applicable with this clinical population as weight loss in healthy 
individuals generally does not involve inflammatory processes. Although the 
subgroup analysis concluded patients with head and neck and oesophageal cancers 
experience metabolic derangements, it is important to consider the inconsistencies 
of the studies used in this subgroup. Given that more studies concerning 
oesophageal cancer were used in the subgroup analysis, this may bias the overall 
REE for this subgroup and may not accurately reflect metabolic alterations in 
patients with head and neck cancer. 
Only one study included in the analyses looked at REE in cirrhotic patients with  
hepatocellular carcinoma (HCC) and documented increased REE. Merli et al[5] 
reported an average increase of 22.68kJ/kg/day FFM with weight-losing patients 
having higher REE than weight-stable patients. Tumour stage was not considered a 
major determinant of REE in cirrhotic patients with HCC as elevations in REE was 
consistently observed amongst patients, and nil correlations between tumour size 
and REE were made. Similar conclusions have been made in regard to other cancer 
types studied by other authors[5, 21, 32, 33]. However, these conclusions are 
opposed to findings from Jebb et al[26] who reported a reduction in REE in lung 
cancer patients when tumour size was reduced, this study used cirrhotic controls 
which may explain the differences in results.  There was only one study included in 
the meta-analysis (Figure 4) which studied REE in urologic cancer patients. Xu et 
al[6] observed a significant increase in REE among cancer patients with kidney and 
adrenal cancers reportedly causing the greatest elevations. A possible explanation 
for observed elevations among HCC and urologic cancer patients may be due to its 
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usual metabolic demands when in a non-diseased state. It has been proposed by 
Holliday, as discussed by Weinsier et al[40], that large internal organs, such as the 
liver and kidneys, could produce similar REE to that of skeletal muscle. Additionally, 
when in a diseased state, the liver serves a role in inflammation and increased 
energy production via gluconeogenesis which could potentially further elevate 
REE[11, 28]. This may mean that some organs become more metabolically 
demanding when they are cancerous and this may contribute to the increased 
metabolic rate. Due to the limited number of studies for both these cancer types, it 
would be difficult to derive any valid conclusions regarding changes in REE. 
Studies investigating gastric and colorectal cancers consistently presented 
insignificant changes in REE when compared to healthy control groups. Cao et al[4]4 
found elevations in gastric cancer patients but observed unchanged REE in patients 
with colorectal cancer. Other authors[3, 7, 16, 18, 19, 21, 29] saw insignificant 
changes. Two studies[3, 16] reported unchanged REE among gastric-colorectal 
cancer patients. However, this could be explained by the authors’ use of the same 
gastric-colorectal cancer patients in both studies. This is important to consider as this 
factor could also affect the findings of this present study. Two authors[16, 28]4 
reported the presence of liver metastasis amongst certain patients with gastric and 
colorectal cancers with mixed conclusions in relation to REE. Fredrix et a[16] 
observed nil elevations in REE amongst patients with liver metastasis, whereas 
Lieffers et al[28] concluded that the presence of metastasis would contribute to 
elevated REE. Given that metastasis would produce a greater tumour burden, it is 
valid to believe REE would be further elevated in these patients. However, this 
review is unable to support this notion due to the small number of included studies 
which reported the effects of metastasis on REE and its conflicting findings.  
Another factor which may affect energy expenditure is gender and whether the 
patients are weight stable or losing weight. Nixon et al[29] reported elevations in 
REE, although not statistically significant, only in weight-losing and weight-stable 
female colon cancer patients whereas male patients experienced slightly lower or 
unchanged REE when compared to control participants despite no correlations being 
made between REE and caloric intake. Although a secondary analysis demonstrated 
there was no difference between weight losing and weight stable patients only 5 
studies reported these subgroups. We also investigated the differences in gender 
however only 2 studies reported results by gender and no differences were found. 
The dataset as a whole contained a larger proportion of males to females (Table 1). 
Although it is anticipated much of the gender difference is related to body 
composition there maybe additional gender specific affects which could not be 
examined in this analysis.  
Limitations and recommendations 
There were a limited number of patients that have been studied in each of the cancer 
subtypes. Results from this study should, therefore, be interpreted with caution as 
more data was available for analysis of REE in lung, gastric and colon cancers. 
Available data for liver pancreatic and head and neck cancers were rather limited, 
and the derived alterations in REE would lack statistical power. Some studies in this 
review were published by the same authors who have utilised the same research 
methodology, and the statistical analyses had several data entries contributed by the 
same authors. Unique subgroups in these papers were analysed as independent 
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samples[15] and the sample size was adjusted to accommodate the use of the same 
control group[14], Despite this some authors may have used the same subject data 
in different studies making the total number of independent subjects uncertain..  
The majority of studies were published before 2000 with only 6 studies published in 
the last 5 years, although we investigated this in a secondary analysis and did not 
see any differences, advances in cancer treatment may have an effect on 
metabolism. Table 1 also shows differences in the methodology used to assess 
energy expenditure (although indirect calorimetry using a ventilated hood was the 
primary method) and body composition methodology. Several studies used field 
methods to assess body composition reducing the quality of the studies although this 
did not have an effect on the results using meta regression. 
This analysis did not consider several other cancers known to raise 
REE.Haematological cancers and sarcomas have been reported to raise REE[41, 
42] and these findings could serve an insightful addition to the current study. Due to 
the exclusion criteria used, these and other studies which published findings about 
other types of cancers not mentioned in this study were unable to be included.  
Studies investigating cancer and metabolic rate often measure REE using body 
weight instead of FFM which resulted in the exclusion of many studies in this 
analysis. Although FFM is often regarded as a more accurate indicator of REE[9, 
10], many studies did not adjust REE for FFM. Furthermore, 40% of the included 
studies used the Harris-Benedict equation (HBE) to compare differences in energy 
expenditure instead of healthy control groups and, therefore, were not used in the 
analyses. It has been widely acknowledged the HBE tend to underestimate REE in 
healthy individuals. Daly et al[43] found the use of HBE to predict energy expenditure 
may not be a valid or reliable approach as it overestimated REE by 10.4% in healthy 
individuals, whereas Campbell et al[44] observed underestimations between 9-23% 
in critically ill and underweight male patients. Therefore, REE derived from the HBE 
may not be applicable to be used as a reference for comparison in cancer patients. 
Therefore, future investigations that measure REE adjusted for FFM and use healthy 
control groups would be advantageous in contributing to current knowledge 
regarding the cancer types discussed in this study and also other cancer types 
known to generate metabolic abnormalities, such as leukaemias. 
Cancer cachexia was often discussed by authors as the background for conducting 
the respective studies. Yet, cachexia was not definitively identified in study patients 
and patients who experienced a large amount of weight loss (>10% of usual body 
weight) may have experienced varying degrees of cachexia. As cachexia greatly 
involves the inflammatory response and altered energy metabolism, REE would 
subsequently increase. If this was the case, the measured REE of patients who 
experienced large amounts of weight loss would skew the results reported by the 
authors and the results of this meta-analysis. 
In conclusion, this meta-analysis supports current evidence of elevated REE in 
cancer patients when compared to healthy control participants with an observed 8-
9% increase. Additionally, this study emphasised the heterogeneity observed among 
cancer types in REE. Due to the exclusion of many studies, not all cancer types were 
included in the meta-analysis as the results were not expressed as REE based on 
FFM. Further investigation of alterations in energy expenditure based on FFM can 
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assist to clarify previous findings, in particular for cancer types not included in this 
review, and to provide renewed data. New data will build the current evidence base 
for the provision of additional nutrition support to compensate for elevated energy 
consumption in metastatic cancer patients[14]. 
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Table 1. Characteristics of studies investigating the alterations in REE per kg FFM in cancer patients. 
Source Study sample number, M/F, Mean 
age 
Control sample number, 
M/F, Mean age 
Study design Methodology used to measure REE & FFM Subjective study summary 
Cao et al. 20104 714 newly detected cancer 
patients.  
150 oesophageal, 154 gastric, 
148 colorectal, 128 pancreatic,  
134 NSCLC  
M/F = 477/237, Age 56 
642 control subjects  
M/F = 445/195 
Age 55.4 
Case control. 
 
Cancer patients & control participants 
recruited from hospital setting. Cancer 
patients were adults, afebrile, nil organ 
dysfunction, nil cancer treatment, nil 
endocrine abnormalities, nil dialysis/fluid 
replacement. 
REE measured via IC using ventilated hood system 
in standard resting conditions (>3hours 
postprandial, 30 minute bed rest). 
 
FFM determined using formula (1.106xECF+1.521x 
ICF). ECF, ICF & total water determined using 
multi-BIA.  
 
FM determined using formula (BW-FFM). 
Cancer patients (all subgroups) had 
higher REE than controls. WL cancer 
patients had higher REE than WS and 
control patients. Stage IV patients had 
higher REE than Stages I-III. Cancer 
type, pathological stage, duration of 
disease responsible for REE.  
Falconer et al. 
199411 
 
21 pancreatic cancer patients. 
M/F = 14/7  
Age 57 
16 control subjects 
M/F = 11/5 
Age 55 
Case control.  
 
Patients with newly detected tumours. Cancer 
patients received nil treatment, afebrile, nil 
infection, nil cholangitis one month prior, nil 
jaundice. Patients had stage 2 (n=7), stage 3 
(n=8) & stage 4 (n=6) using Union 
Internationale Contre le Cancer TNM 
classification. 
 
Control participants admitted for minor 
elective surgical procedures. 
REE via IC using a ventilated hood system after 
overnight fast in resting conditions.  
 
FFM measured via BIA. 
 
Pancreatic cancer patients had higher 
REE than controls. 
 
Fearon et al. 
19887 
 
20 lung cancer patients. 
M/F = -, Age 60 
38 colon cancer patients 
M/F=-, Age 64.5 
22 control subjects (non-
neoplastic diseases).  
M/F = -, Age 58.8 
Case control.  
 
Lung cancer patients with nil previous 
treatment two months prior. Stage 2 (n=9) & 
stage 3 (n=11) using WHO classification. 
Colon cancer patients studied prior to 
laparotomy. Stage B (n=16), stage C (n=11), 
stage D (n=10) using Dukes’ classification. 
 
Control participants had non-neoplastic 
disease.  
REE via IC with a rigid canopy (sensitive 
paramagnetic oxygen analyser) & an IR carbon 
dioxide analyser. Patients were fasted overnight & 
at rest for 30 minutes.  
 
FFM derived from measurements of total body 
water. 
Nil significant difference in REE 
between both cancer groups and 
controls.  
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Fredrix et al. 
199134 
 
104 gastric/colorectal patients 
(25/104 had liver metastases; 
41/104 had stages 1 and 2; 63/104 
had stages 3 & 4).  
M/F = 54/50, Age 70 
72 control subjects  
32 GI diseases 
M/F GI = 20/12, Age 64 
40 healthy 
M/F = 18/22 Age 65 
Case control.  
 
Patients with newly detected cancer & nil 
previous treatment.  
 
Control participants with non-malignant GI 
diseases.  
REE calculated using abbreviated Weir formula. 
Ventilated hood system used to measure gas 
exchange. Cancer patients were fasted overnight 7 
after >30minute bed rest. REEs of cancer patients 
& some control participants measured during 
hospital stay. REE of remaining control participants 
measured on an outpatient basis. 
 
FFM estimated using BIA & calculated using 
formula of Segal.  
REE not elevated in GCR- cancer 
patients compared to controls.  
Nil association between increased REE 
and cancer stage. 
 
Fredrix et al. 
19913 
 
104 gastric/colorectal patients  
M/F = 54/50, Age 70 
47 NSCLC patients 
M/F = 43/4, Age 66  
40 healthy controls  
M/F = 18/22 
Age 65 
Patients with newly detected cancer & nil 
previous treatment.  
 
Control participants had nil conditions which 
may affect metabolic rate. 
REE via IC using ventilated hood system & 
calculated using abbreviated Weir formula. 
Patients were fasted overnight & were rested >30 
minutes.  
 
FFM estimated via BIA & calculated using formula 
of Segal. BIA was used in only half of GCR patients 
due to nil equipment availability at beginning of 
study.  
Lung cancer patients have elevated 
REE, while GCR cancer patients have 
unchanged REE.  
Surgical resection normalises REE in 
lung cancer patients.  
Cancer type contributes to REE. 
Fredrix et al. 
199735 
 
53 NSCLC patients (pre-surgery); 39 
patients (post-surgery)  
M/F no recurrence = 20/10 
M/F tumour recurrence = 8/1. Age 
65.5 
NSCLC patients acted as 
their own controls 
Pre-test/Post-test. 
 
Cancer patients had newly detected primary 
NSCLC. Nil previous treatment, afebrile, nil 
high doses of steroids, nil severe endocrine 
abnormalities.  
REE measured by IC using ventilated hood system 
after overnight fast & were rested for >20 minutes. 
Post resection REE measured on an outpatient 
basis. REE calculated using abbreviated Weir 
formula. 
 
FFM estimate using BIA. FFM = total body 
water/0.73. 
 
REE measured prior to patients undergoing 
surgery. REE also measured 3, 6 & 12 months post 
resection.  
REE reduced slightly after surgery in 
hyper-metabolic patients.   
Fredrix et al. 
199136 
 
30 NSCLC patients  
M/F = 27/3, Age 65  
104 gastric/colorectal patients  
M/F = 54/50, Age70 
Nil Post-test. 
 
Cancer patients had newly detected NSCLC & 
had nil previous treatment.  
 
REE measured by IC using ventilated hood system 
after overnight fast & 30 minute rest period. REE 
calculated using abbreviated Weir formula. 
 
FFM estimated using BIA & calculated using 
formula of Segal.  
REE elevated in lung cancer patients.  
Strong correlation between increased 
REE and weight loss in lung cancer 
patients. 
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Fredrix et al. 
199037 
 
39  
22 GCR patients 
M/F = 13/9, Age 68 
17 lung patients 
M/F = 16/1, Age 68 
40 healthy controls  
M/F = 18/22  
Age 65 
Case control. 
 
Cancer patients had newly detected tumours 
& had nil previous treatment.  
 
Control participants were healthy. Nil health 
conditions reported.  
REE measured via IC using ventilated hood system 
after overnight fast & rested for >30 minutes. 
 
BIA used to measure body composition. FFM 
estimated using formula of Segal. 
REE elevated in lung cancer patients. 
Tumour type affects REE. Reduced EI in 
GCR patients explained weight loss as 
REE is unchanged. Increased REE and 
low EI explained weight loss.  
Garcia-Peris et 
al. 200522 
 
18 H&N patients (stages 3 & 4)  
M/F = 15/3, Age 57 
Nil Pre-test/post-test.  
 
H&N cancer patients (stage 3 & 4) without 
distant metastasis. Nine patients had previous 
radical surgery. All patients treated with 
radiotherapy & concurrent chemotherapy.  
REE measured via IC (open circuit calorimeter) 
after overnight fast. REE calculated using Weir 
formula.  
 
Tetrapolar, single frequency Holtain BC analyser 
(BIA) to measure body composition. FFM 
calculated using software provided by 
manufacturer. 
 
REE & FFM measured before treatment, at weeks 
2, 4 & 6, and 2 weeks post treatment.  
REE decreases during chemotherapy 
but normalises at the end of treatment. 
Effects of treatment may contribute to 
reduced REE. FFM increased which may 
explain increased REE and weight loss.  
Hansell et al. 
198638 
 
24 colon 
Tumour-bearing  
M/F = 5/4, Age 68 
Tumour-free  
M/F = 8/7, Age 65 
Each patient acted as 
his/her own control 
Pre-test/post-test. 
 
Cancer patients had nil infection, nil 
treatment.  
 
Tumour-bearing patients had hepatic 
metastasis. Tumour-free patients showed nil 
hepatic metastasis.  
REE measured using IC with rigid canopy after 
overnight fast & 30 minute rest period. REE 
calculated using Weir’s formula. 
 
FFM derived from measurement of total body 
water assuming lean tissue contains 73% water 
(urine collected 3 & 4 hours after tritium 
injections). 
 
REE & FFM measured pre-operatively and post-
operatively. 
REE between tumour-free and tumour-
bearing patients showed nil significant 
difference. Colon cancer had nil effect 
on REE.  
Hansell et al. 
198614 
 
84 patients 
51 colorectal  
M/F = 29/22, Age 67 
22 gastric  
M/F = 14/8, Age 67 
11 bronchial  
M/F = 9/2, Age 61 
Nil Case series. 
 
Cancer patients had nil infection, nil 
treatment.  
REE measured via IC with rigid canopy after 
overnight fast & after 30 minute rest period.  REE 
calculated using Weir formula.  
 
FFM derived from measurement of total body 
water assuming lean tissue contains 73% water 
(urine collected 3 & 4 hours after tritium 
injections). 
Nil significant difference in REE 
between cancer groups. 
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Hansell et al. 
198639 
 
98 patients 
(91 GCR & 7 bronchial) 
56 WS  
M/F = 40/16, Age 66 
42 WL  
M/F = 23/19, Age 65 
38 control patients  
22 WS  
M/F = 6/16, Age 62 
16 WL  
M/F = 8/8, Age 63 
Case control. 
 
Cancer patients had nil infection & nil prior 
treatments.  
 
Control patients had non-malignant diseases 
(peptic ulcerations, choleithiasis, others). 
 
Liver metastasis present in 11 WS patients & 8 
WL patients.  
REE measured via IC with rigid canopy after 
overnight fast & after 30 minute rest period.  REE 
calculated using Weir formula.  
 
FFM derived from measurement of total body 
water assuming lean tissue contains 73% water 
(urine collected 3 & 4 hours after tritium 
injections). 
Nil significant difference in REE 
between cancer patients and controls. 
Tumour type had no influence on REE.  
Patients’ metabolic response to non-
malignant illness may determine 
changes in REE. 
Harvie et al. 
200540 
41 patients  
19 NSCLC  (Stage 3 or 4) 
M/F = 15/4, Age 59 
12 metastatic melanoma  
M/F = 9/3, Age 54 
10 metastatic breast  
M/F = 0/10, Age 56 
Healthy control 
participants also recruited. 
Number of participants 
not reported & only REE 
measured in this group. 
Pre-test/Post test. 
 
Cancer patients received nil treatment within 
previous 3 months.  
 
Control participants recruited by hospital staff.  
REE via IC under standardised conditions. REE also 
measured in control participants but not reported. 
 
FFM determined using total body potassium 
(NE8108 shadow shield whole body monitor).  
 
Patients seen prior to commencing chemotherapy, 
prior to 2nd chemotherapy cycle & 1 month post 
completion of chemotherapy. 
REE elevated in NSCLC patients and 
normal in breast cancer and melanoma 
patients.  
 
Harvie et al. 
200441 
17 female breast cancer patients, 
Age 46 
21 controls, Age 45 Pre-test/post-test. 
 
Cancer patients with newly diagnosed invasive 
breast cancer recruited by telephone prior to 
commencing adjuvant chemotherapy & within 
3 weeks of breast surgery. Patients received 
nil previous treatment, had nil endocrine 
abnormalities or psychiatric morbidity. 
 
Healthy control participants recruited by 
hospital staff. 
REE via IC using open circuit ventilated hood 
system after overnight fast & 20 minute rest 
period. REE calculated using Weir formula. 
 
FFM measured using total body impedance (total 
body water) via tetrapolar impedance meter. 
 
REE measured in both groups but results of control 
group not reported.  
Higher REE in breast cancer patients, 
may be due to surgery.  
Jebb et al. 
199442 
28 small cell lung cancer  
18 responders  
M/F = 12/6, Age 63  
10 non-responders 
M/F = 8/2, Age 60 
Nil Pre-test/post-test. 
 
SCLC patients recruited over a 12 month 
period in outpatient clinics. Patients received 
nil prior treatment.  
REE measured using portable IC after overnight 
past & 30 minute rest period. REE calculated using 
equation of Elia & Livesey. 
 
FFM determined using LUNAR-DPX scanner. 
 
REE & body composition measured at baseline & 1 
month post-treatment.  
Reduction in tumour mass resulted in 
reductions in REE independent of body 
composition. Tumours have the ability 
to increase REE. 
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Langius et al. 
201220 
71  H&N cancer patients  
M/F = 45/26, Age 65 
40 healthy controls  
M/F = 20/20, Age 59 
Pre-test/post-test, observational. 
 
Cancer patients receiving primary or 
postoperative radiotherapy.  
 
Nil patients with distant metastasis, 
thyroid/inflammatory diseases, receiving 
concurrent chemotherapy or receiving 2nd 
dose of radiotherapy.  
 
Healthy control participants recruited through 
advertisement on internet & in 
hospital/university campus. 
REE measured via IC prior to treatment, after 3 
weeks of treatment, at the end of treatment, and 
12 weeks after completion of treatment. Patients 
& participants were at complete rest for 30 
minutes & REE calculated using Weir equation. 
 
FFM assessed using single-frequency BIA. FFM 
calculated using validated equation of Kyle.  
 
REE of cancer patients pre-treatment was 
compared to REE of control participants.  
REE didn't differ to controls before 
treatment but decreased during and 
after treatment. 
Lieffers et al. 
200929 
18 colorectal cancer patients   
Age 60 
Nil Case series. 
 
Cancer patients recruited from the Cross 
Cancer Institute (Canada).  
REE via IC (after 12 hour fast & 30 minute rest 
period. REE calculated using Weir equation.  
 
FFM measured via dual x-ray absorptiometry scan. 
Metastatic disease and organomegaly 
can elevate REE. 
Variances in REE depend on types of 
FFM (i.e. major organs vs. skeletal 
muscle). 
Merli et al. 
19925 
12 cirrhotic patients with HCC  
M/F = 6/6, Age 64 
12 cirrhotic patients 
without HCC  
M/F = 6/6, Age 55 
Case control. 
 
Cancer patients had nil prior treatment.  
 
Control patients without HCC selected based 
on similar body weight & height to cancer 
patients.  
REE measured using a metabolic-measurement 
cart with a canopy system after overnight fast & 30 
minute rest period.  
 
FFM calculated using the method of Durnin & 
Womersley via skin fold tests (biceps, tricepts, 
suprailiac & subscapular). 
REE increased in cirrhotic patients with 
HCC. Tumour stage not determinant of 
REE.  
 
Nixon et al. 
198816 
98 patients  
46 colon  
M/F = 30/15, Age 58.5 
52 NSCLC  
M/F = 27/11, Age 57.5 
104 controls, 60 healthy 
M/F = 17/43, Age ≥40 
5 anorexia nervosa 
9 non-neoplastic GI 
disorders 
12 protein-energy 
malnutrition 
9 chronic lung disease 
Case control. 
 
Cancer patients admitted to Emory Clinical 
Research Facility or the Emory Oncology 
Ward. Patients had nil surgery >21 days prior, 
nil acute/chronic diseases, nil 
alcohol/tranquiliser abuse.  
 
Control participants divided into 5 groups. 
REE measured using direct gradient-layer whole-
body calorimetry after overnight fast & 15 minute 
rest period. Chemotherapy patients studied prior 
to commencing chemotherapy cycle. 
 
FFM derived from body weight & skin fold 
measurements. FFM calculated using Durnin & 
Womersley method.  
REE didn't differ between cancer types 
and controls.  
REE elevated in WL female lung & colon 
cancer patients.  
REE generally higher in WL cancer 
patients. 
Nguyen 
 
18 
Silver et al. 
200721 
17 Stage III & IVa H&N cancer 
patients  
M/F = 15/2, Age 59 
Nil Pre-test/post-test. 
 
Cancer patients recruited from the Vanderbilt-
Ingram Cancer Center. Patients studied prior 
to commencing radiotherapy & 1 month post 
treatment. 
REE via IC with open-circuit system after an 8-hour 
fast & 60 minute rest period.  
 
FFM assessed using dual-energy x-ray 
absorptiometry. 
Elevated REE 1 month post 
chemoradiation.   
 
Staal-van den 
Brekel et al. 
199417 
100 lung patients  
M/F = 82/18, Age 65 
Nil Case series. 
 
Cancer patients had nil previous treatment, nil 
steroid treatment, nil severe endocrine 
abnormalities, afebrile. 
REE measured by IC using ventilated hood system 
after an overnight fast at complete rest. 
 
FFM assessed using single frequency BIA & 
calculated using patient specific regression 
equation (FFM = 8.9+0.5x[height2/resistance]). 
Central tumour localisation and 
inflammation contribute to increased 
REE. WL due to increased REE and 
decreased intake. Higher REE in WL 
patients. 
Thomson et al. 
199023 
14 patients with oesophageal 
cancer  
M/F = 9/5, Age 54.5 
17 controls (benign 
disease) M/F = 11/6  
Age 56 
Case control. 
 
Cancer patients admitted to King Edward the 
VIII Hospital. Patients were studied prior to 
surgery. 
 
Control participants admitted for minor 
procedures. 
REE via IC after overnight fast & calculated using 
modified equations from other authors. 
 
FFM derived from skin fold thickness using the 
tables from Durnin & Womersley. 
Tumour had little effect on REE. 
Changes in REE were secondary to 
changes in body composition. 
Trutschnigg et 
al. 20138 
8 female advanced cancer patients 
over 65yrs (cholangiocarcinoma, 
colon, liver, pancreatic, NSCLC)   
M/F = 0/8, Age 73 
11 healthy female controls 
over 65yrs  
M/F = 0/11, Age76 
Case control. 
 
Patients & controls recruited through 
advertisement & physician referrals from 
Royal Victoria Hospital & the Hepato-
Pancreato-Biliary Cancer Centre of the McGill 
University Health Centre. 
REE measured using IC & calculated using the Weir 
equation.  
 
FFM determined using dual-energy x-ray 
absorptiometry. 
REE not significantly different between 
groups.  
Vaisman et al. 
201218 
45 pancreatic cancer patients (15 
post-operative; 30 advanced)  
M/F =-, Age 57 
75 healthy controls  
Age 57  
Case control, cross sectional study. REE measured by IC after overnight fast and 20 
minute rest period. 
 
FFM measured via dual-energy x-ray 
absorptiometry. 
REE not significantly different between 
groups. Resection of tumour does not 
influence REE.  
 
Nguyen 
 
19 
Weston et al. 
198924 
30 cancer patients (gastro-
oesophageal, colorectal, other GI 
cancer).  
M/F WS = 15/5, Age 64 
M/F WL = 5/5, Age 71 
7 benign controls  
M/F = 3/4  
Age 66 
Case control. 
 
Cancer & control patients studied prior to 
surgery.  
 
Control patients had non-malignant 
gastrointestinal disease.  
REE via IC after an 8 hour overnight fast & 
calculated using Weir formula. 
 
FFM derived from total body potassium & 
calculated using values derived by other authors. 
WL patients had higher REE but nil 
significant difference in REE between 
groups.  GI cancer patients have nil 
changes in REE. 
Wu et al. 201325 56 male oesophageal cancer 
patients 
M/F = 56/0, Age 61 
30 healthy controls  
Age 62 
Case control. 
 
Cancer patients recruited from Xin Hua 
Hospital. Patients had nil previous treatment, 
afebrile, nil severe endocrine abnormalities, 
nil dialysis/fluid replacement.  
REE measured via open-circuit IC via ventilated 
hood system 3 hours post-prandial and 30 minute 
bed rest. REE calculated using Weir equation. 
 
FFM determined using four-lead BIA. 
REE of cancer patients significantly 
increased compared to controls.  
Xu et al. 20126 122 urologic cancer patients  
74 kidney, 31 bladder,  17 adrenal  
M/F = 72/50, Age 55 
131 non malignant 
controls  
M/F = 75/56, Age 54 
Case control. 
 
Cancer patients & control participants 
recruited from Zhongshan Hosptial, Fudan 
University at time of primary diagnoses. 
REE via IC using ventilated hood system & 
calculated using equation: mREE=5.50xVO2 
+1.76xVCO2 
 
FFM determined using multi-BIA from ICF & ECF, 
using equation: FFM=1.106xECF+1.521xICF. 
 
REE & FFM measured pre-operatively. 
REE significantly elevated in cancer 
patients. REE can be influenced by 
tumour type and tumour stage.  
 
REE, resting energy expenditure; FFM, fat free mass; NSCLC, non small cell lung carcinoma; M, male; F, female; -, gender distribution unspecified;  WS, weight stable; WL, weight loss; GCR, gastric-colorectal; EI, 
energy intake; H&N , head & neck; HCC, hepatocellular carcinoma; IC, indirect calorimetry; BIA, bioelectrical impedance analysis. 
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Figure 1. Mean REE/FFM is significantly higher in cancer patients. The size of the 
shaded squares is proportional to the weight of each study. The horizontal lines 
represent 95% CI. Multiple entries from the same paper represent figures presented 
divided by cancer subtype, weight losing/weight stable and/or sex. 
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Figure 2. Subgroup analysis showing elevations in REE for each cancer subtype. The 
size of the shaded squares is proportional to the weight of each study. The horizontal 
lines represent 95% CI.  1Lung; 2Gastric/colon; 3Head, neck and oesophageal; 4Liver; 
5Pancreatic. Multiple entries from the same paper represent figures presented divided 
by cancer subtype, weight losing/weight stable and/or sex. 
NOTE: Weights are from random effects analysis
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Figure 3 Funnel Plot 
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Figure 4 
 
WMD weighted mean difference, se standard error, 1-6, indicates the different cancer types as 
labelled. 
 
NOTE: Weights are from random effects analysis
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Figure 5 Funnel plot for subgroup analysis 
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